论文部分内容阅读
引言由于成人急性白血病治疗的最新进展,完全缓解率(C.R.)和存活时间有了提高,但大多数患者在二年内因复发而死亡。成人急性原粒细胞性白血病(A.M.L.)初次复发后,予后很差,只有30％获得短期的第二次缓解。生存期只有18周。第二次复发的急性淋巴细胞性白血病(A.L.L)以及急性未分化性白血病(A.U.L)的生存期与第一次A.M.L.复发患者的生存期相同。复发白血病的难治性,可能用大剂量化疗、全身照射(T.B.I.)及HLA相同的混合淋巴细胞培养阴性的同种异体骨髓移植来克服。但是合适的供髓者很少。作者的病例只有30％有
INTRODUCTION Due to recent advances in the treatment of adult acute leukemia, complete remission (CR) and survival have been improved, but most patients die of relapse within two years. After the first relapse of adult acute myeloid leukemia (A.M.L.), the pre-treatment was very poor, and only 30% achieved the second short-term relief. Survival of only 18 weeks. The second relapse of acute lymphoblastic leukemia (A.L.L) and acute undifferentiated leukemia (A.U.L) had the same survival as the first A.M.L. relapse. The refractory nature of recurrent leukemia may be overcome by high-dose chemotherapy, total body irradiation (T.B.I.) and HLA-identical mixed lymphocyte culture-negative allogenic bone marrow transplantation. However, there are few suitable donors. Only 30% of the authors have cases